This article first appeared on GuruFocus.

Eli Lilly (NYSE:LLY) just landed a meaningful international win after India's drug regulator approved donanemab, the company's Alzheimer's treatment for people in the very early stages of the disease. Lilly expects the medicine to hit the Indian market within the next few months, giving the therapy a major new foothold outside the U.S.

Warning! GuruFocus has detected 4 Warning Sign with AMZN.

Is LLY fairly valued? Test your thesis with our free DCF calculator.

Pricing is still a big open question. Lilly hasn't shared its India plans yet, but the drug currently costs about $32,000 a year in the U.S., which comes to roughly Rs 28.34 lakh. The final price for India will depend on things like local manufacturing, import duties and regulatory requirements, all of which could determine how accessible the treatment becomes once it launches.

The approval comes at a time when awareness around Alzheimer's and early detection is growing quickly in India, making it an important market for new therapies like donanemab.

For investors, this marks another step in Lilly's global rollout. The key thing to watch next is how the company approaches pricing and availability ahead of the launch.